HomeMarketsPublished: June 24, 2026 at 8:11 a.m. ET
Blackstone’s decision to cap withdrawals from its flagship fund is a “feature and not a flaw” of the system, designed to “protect investors from themselves,” according to one strategist.
At the beginning of June, the New York–based investment-management company said it was limiting redemptions from its $82 billion Blackstone Private Credit Fund, known as BCRED, to 5% of shares after a rise in requests. The move came after investors in the fund tried to redeem 8% in the first quarter and 10% in the second quarter, as concerns grew over artificial intelligence’s potential to disrupt the industry as a whole.
About the Author
Nora Redmond is a MarketWatch reporter based in London.
Chipotle Mexican Grill (CMG - Free Report) closed at $30.95 in the latest trading session, marking a +1.34% move from the prior day. The stock's change was more than the S&P 500's daily loss of 1.44%. On the other hand, the Dow registered a loss of 0.09%, and the technology-centric Nasdaq decreased by 2.22%.
The stock of Mexican food chain has fallen by 7.15% in the past month, lagging the Retail-Wholesale sector's loss of 6.89% and the S&P 500's gain of 0.08%.
The investment community will be closely monitoring the performance of Chipotle Mexican Grill in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. The company is expected to report EPS of $0.32, down 3.03% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $3.32 billion, showing a 8.25% escalation compared to the year-ago quarter.
CMG's full-year Zacks Consensus Estimates are calling for earnings of $1.13 per share and revenue of $12.93 billion. These results would represent year-over-year changes of -3.42% and +8.4%, respectively.
Any recent changes to analyst estimates for Chipotle Mexican Grill should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% higher. Chipotle Mexican Grill is currently sporting a Zacks Rank of #3 (Hold).
Looking at valuation, Chipotle Mexican Grill is presently trading at a Forward P/E ratio of 26.99. This expresses a premium compared to the average Forward P/E of 19.12 of its industry.
We can additionally observe that CMG currently boasts a PEG ratio of 1.97. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. CMG's industry had an average PEG ratio of 1.89 as of yesterday's close.
The Retail - Restaurants industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 199, positioning it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Chipotle (CMG +1.89%) is accelerating the pace of development.
*Stock prices used were the afternoon prices of June 20, 2026. The video was published on June 22, 2026.
Parkev Tatevosian, CFA has positions in Chipotle Mexican Grill. The Motley Fool has positions in and recommends Chipotle Mexican Grill. The Motley Fool recommends the following options: short June 2026 $36 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
, /PRNewswire/ -- PBF Energy Inc. (NYSE:PBF) announced today that it will release its earnings results for the second quarter 2026 on Thursday, July 30, 2026. The company will host a conference call and webcast regarding results and other business matters on Thursday, July 30, 2026, at 8:30 a.m. ET.
The call is being webcast and can be accessed on PBF Energy's website, http://www.pbfenergy.com. The call can also be accessed by dialing (800) 549-8228 or (646) 564-2877. The audio replay will be available approximately two hours after the end of the call and will be available on the company's website.
About PBF Energy Inc.
PBF Energy Inc. (NYSE: PBF) is one of the largest independent refiners in North America, operating, through its subsidiaries, oil refineries and related facilities in California, Delaware, Louisiana, New Jersey and Ohio. Our mission is to operate our facilities in a safe, reliable and environmentally responsible manner, provide employees with a safe and rewarding workplace, become a positive influence in the communities where we do business and provide superior returns to our investors.
PBF Energy is also a 50% partner in the St. Bernard Renewables joint venture focused on the production of next generation sustainable fuels.
Contacts:
Colin Murray (investors)
[email protected]
Tel: 973.455.7578
Michael C. Karlovich (media)
[email protected]
Tel: 973.455.8981
PBF Energy (PBF - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PBF crossed above the 20-day moving average, suggesting a short-term bullish trend.
A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.
Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend.
Shares of PBF have been moving higher over the past four weeks, up 6.4%. Plus, the company is currently a Zacks Rank #3 (Hold) stock, suggesting that PBF could be poised for a continued surge.
Looking at PBF's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 5 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.
Investors should think about putting PBF on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
On June 24, 2026, we delve into the DCF analysis for Intercontinental Exchange Inc ICE , a company that has experienced notable price performance fluctuations recently. The stock has seen a decline of 5.9% over the past week, 12.7% over the past month, 17.3% year-to-date, and a significant 25.1% over the past year.
DCF Earnings-based intrinsic value of $128.85 vs current price of $133.00 (margin of safety: -3.2%) DCF FCF-based intrinsic value of $134.64 vs current price (second opinion: fair valued with 1.2% margin of safety) GF Score™ of 86/100, indicating a high reliability of the DCF inputs What Is ICE Worth? DCF Earnings-Based Model The DCF earnings-based model for ICE utilizes a two-stage approach to estimate the intrinsic value of the stock. In the first stage, we project earnings growth over the next ten years, followed by a terminal growth phase. The assumptions used in this model are outlined in the table below:
Parameter Value Current EPS (TTM, excl. non-recurring) $7.58 10-Year Growth Rate 10.9% 10-Year Treasury Rate 4.49% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the first stage, we expect EPS to grow at a rate of 10.9% annually for the next ten years, which is then discounted at a rate of 11%. The value derived from this growth stage is $75.43 per share. Following this growth phase, we transition into the terminal stage where growth slows to a 4% rate for the subsequent ten years, also discounted at 11%. The terminal stage value is calculated at $53.42 per share. The summary of the calculation is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 10.9%, discounted at 11% $75.43 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $53.42 Intrinsic Value Growth + Terminal $128.85 Comparing the current price of $133.00 to the intrinsic value of $128.85 indicates that ICE is fairly valued, with a margin of safety of -3.2%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research shows that stock prices tend to correlate more closely with earnings than with free cash flow. For a detailed breakdown, visit the ICE DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF)-based intrinsic value for ICE is calculated at $134.64. This value provides a second opinion on the valuation of the stock. When compared to the earnings-based intrinsic value of $128.85, both models suggest that ICE is fairly valued, with the FCF model indicating a 1.2% margin of safety.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for ICE stands at $165.59, offering a third perspective on the valuation of the stock. GF Value™ is GuruFocus' proprietary measure, calculated based on historical trading multiples, past business growth, and future performance estimates. While the DCF models indicate that ICE is fairly valued, the GF Value™ suggests that the stock may be undervalued, creating a divergence in valuation perspectives. For further insights, visit the GF Value™ page.
What Does ICE's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtested data from 2006 to 2021. The current GF Score™ for ICE is 86/100, indicating strong fundamentals. The table below summarizes the key metrics:
Metric Rating GF Score™ 86/100 Financial Strength 4/10 Profitability 8/10 Growth 10/10 Valuation 8/10 Momentum 4/10 With a predictability rank of 2/5 stars, it is important to note that higher predictability ratings generally lead to more reliable DCF estimates. For more details, visit the ICE stock page.
Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as ICE's 2/5 stars, may produce less reliable DCF estimates. Additionally, the terminal growth rate of 4% is a simplifying assumption that may not reflect future economic conditions accurately.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find that ICE is fairly valued based on the DCF models, while the GF Value™ suggests a potential undervaluation. This divergence indicates that investors should consider multiple perspectives before making decisions. For the full DCF analysis, visit the ICE DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is ICE's intrinsic value based on DCF?
Answer: earnings-based $128.85, FCF-based $134.64
Is ICE overvalued or undervalued?
Answer: Based on DCF models, ICE is fairly valued; however, GF Value™ suggests it may be undervalued.
How reliable is the DCF model for ICE?
Answer: The DCF model's reliability is moderate, indicated by a predictability rank of 2/5.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Qorvo (QRVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Key Takeaways Z-Flex generated more than $480M in TCV in Q3, rising more than 60% sequentially for Zscaler.Zscaler saw ARR rise 25% YoY to over $3.5B, while remaining performance obligations grew 30% to $6.5B.Z-Flex helped large clients increase spending by adding new modules, like AI Protect and Zero Trust Branch. Zscaler Inc.’s (ZS - Free Report) Z-Flex program is emerging as an important growth driver for the company. The offering allows customers to make multi-year commitments while giving them the flexibility to activate or switch products without going through a new purchasing process. This approach is helping Zscaler increase customer spending, improve visibility and strengthen long-term relationships.
The momentum behind Z-Flex accelerated during the third quarter of fiscal 2026. Z-Flex generated more than $480 million in the total contract value (TCV) during the quarter, representing growth of more than 60% sequentially. Over the last 12 months, Zscaler delivered more than $1 billion in Z-Flex TCV with an average contract duration of four years.
The program is also encouraging broader platform adoption. Several large customers expanded their use of existing products while adding new modules, including AI Protect and Zero Trust Branch solutions. During the last earnings call, management revealed that one large financial customer increased annual spending by nearly 50%, while another enterprise customer expanded its spending by 60%.
The strong uptake of Z-Flex is contributing to Zscaler’s overall growth. During the third quarter, annual recurring revenues (ARR) rose 25% year over year to more than $3.5 billion. Remaining performance obligations increased roughly 30% to $6.5 billion, providing strong revenue visibility. Total third-quarter revenues rose 25% year over year to $850.4 million.
Management believes Z-Flex shortens sales cycles, increases upselling opportunities and improves customer retention. As enterprises continue consolidating cybersecurity vendors and adopting broader Zero Trust platforms, Z-Flex could remain a meaningful catalyst for Zscaler’s long-term growth and revenue expansion. The Zacks Consensus Estimate for Zscaler’s fiscal 2026 revenues is pegged at $3.33 billion, indicating 24.6% year-over-year growth.
How Do ZS’ Rivals Compare in Flexible Customer Contracts?Two major cybersecurity companies competing with Zscaler in long-term customer engagements are Palo Alto Networks, Inc. (PANW - Free Report) and CrowdStrike Holdings, Inc. (CRWD - Free Report) .
Palo Alto Networks has successfully pushed its platformization strategy, encouraging customers to consolidate multiple security products under one vendor. In the third quarter of fiscal 2026, the company’s next-generation security ARR jumped 60% year over year to $8.1 billion, reflecting strong customer commitment to multi-product contracts.
Palo Alto Networks’ bundled offerings across network security, cloud security and security operations help improve customer retention and expand spending over time. This strategy shares similarities with Zscaler’s Z-Flex program, which promotes broader platform adoption through multi-year agreements.
CrowdStrike has also benefited from higher customer consolidation trends. The company’s ARR rose 24% year over year to $5.5 billion in the first quarter of fiscal 2027. More customers continue adopting multiple Falcon modules, helping expand contract values and increase retention rates. CrowdStrike’s subscription-based model provides recurring revenue visibility similar to Zscaler’s long-term commitments.
While both competitors, Palo Alto Networks and CrowdStrike, focus on platform expansion, Zscaler’s Z-Flex program offers customers additional flexibility to activate or swap products during contract periods, which strengthens its upselling opportunities and long-term revenue growth.
Zscaler’s Price Performance, Valuation & EstimatesZS shares have plunged 44.8% year to date against the Zacks Security industry’s rise of 43.2%.
Zscaler YTD Price Return Performance
Image Source: Zacks Investment Research
From a valuation standpoint, ZS trades at a forward price-to-sales ratio of 5.22, significantly below the industry’s average of 15.65.
Zscaler Forward 12-Month P/S Ratio
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Zscaler’s fiscal 2026 and 2027 earnings implies year-over-year increases of 25.9% and 10.9%, respectively. Estimates for fiscal 2026 and 2027 have been revised upward over the past 30 days.
Image Source: Zacks Investment Research
Zscaler currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zscaler, Inc. (“Zscaler” or the “Company”) (NASDAQ: ZS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Zscaler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 26, 2026, Zscaler reported its financial results for the third quarter of its 2026 fiscal year. Although Zscaler’s revenue and earnings exceeded expectations, the Company guided for current-quarter revenue of between $875 million to $878 million, falling short of the $879 million consensus expectation.
On this news, Zscaler’s stock price fell $58.19 per share, or 31.52%, to close at $126.41 per share on May 27, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.
The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.
Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.
The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.
With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.
Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.
Stocks with a #3 (Hold) ranking, which is most stocks covered at 60%, are expected to perform in-line with the broader market. But stocks that fall into the #2 (Buy) and #1 (Strong Buy) ranking, or the top 15% and top 5% of stocks, respectively, should outperform the market. Strong Buy stocks should outperform more than any other rank.
Should You Consider Phillips 66?The final step today is to look at a stock that meets our ESP qualifications. Phillips 66 (PSX - Free Report) earns a #2 (Buy) 30 days from its next quarterly earnings release on July 24, 2026, and its Most Accurate Estimate comes in at $6.99 a share.
Phillips 66's Earnings ESP sits at +14.21%, which, as explained above, is calculated by taking the percentage difference between the $6.99 Most Accurate Estimate and the Zacks Consensus Estimate of $6.12. PSX is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
PSX is part of a big group of Oils and Energy stocks that boast a positive ESP, and investors may want to take a look at ConocoPhillips (COP - Free Report) as well.
Slated to report earnings on August 6, 2026, ConocoPhillips holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $3.42 a share 43 days from its next quarterly update.
ConocoPhillips' Earnings ESP figure currently stands at +14.26% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $2.99.
PSX and COP's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.
Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
Now Available, Veeva Falcon MLR Delivers Agentic MLRTM to Significantly Reduce Manual Effort and Shorten Review Cycles
, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced it has acquired Copli, the pioneer in agentic medical, legal, and regulatory (MLR) solutions for the life sciences industry. Copli is now available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years.
Veeva Falcon MLR brings agentic automation to marketing teams, MLR groups, and agencies. It executes rigorous reviews of promotional and medical materials, conducting compliance checks against approved labels and local regulations, to minimize manual effort and free reviewers for higher value work.
"Our breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval," said Jacob Scheel-Bech, CEO of Copli. "As part of Veeva, we can scale our vision for MLR transformation. Veeva Falcon MLR brings compliance at speed to the industry with intelligent agents that work seamlessly with Veeva PromoMats."
"The MLR process has long been a significant bottleneck in getting critical information to patients and doctors," said Emma Hyland, vice president, Veeva Commercial Content. "With Veeva Falcon MLR, our customers can speed up the entire review cycle, automating routine labor so reviewers can become strategic advisors."
To learn more about Veeva Falcon MLR register for the upcoming webinar on July 9 at 10 a.m. ET or visit FalconMLR.veeva.com.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements about the expected results and benefits from our acquisition of Copli. These statements are based on our current plans, estimates, and expectations. Acquisitions are risky, and we cannot be certain of success. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. We describe the risks and uncertainties that we believe are most relevant to our business, including risks associated with acquisitions, in our periodic SEC filings, which you can access at sec.gov.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
NASHVILLE, Tenn.--(BUSINESS WIRE)--LP Building Solutions (LP), a leading manufacturer of high-performance building products, broke ground on a new LP® SmartSide® ExpertFinish® Trim & Siding manufacturing facility today in North Branch, Minnesota. The approximately 350,000-square-foot facility will be built on a recently acquired 120-acre site. It is expected to create 125 jobs at full capacity and is slated to begin production in the first quarter of 2028.
Rocket Lab stock price has slipped in the past few weeks as investors book profits following the spectacular rally that happened before the SpaceX IPO. RKLB dropped to the key support level of $100, even after it entered the exclusive Nasdaq 100 Index. Still, there are some reasons why it will eventually rebound.
RKLB stock has retreated sharply this month, moving from a record high of $151 to slightly below $100 on Monday. This retreat happened on the day that it entered the Nasdaq 100 Index, a move that has forced ETFs tracking it to buy.
Technicals suggest that there is hope that the Rocket Lab shares will bounce back despite the major challenges. For one, it has dropped and found support at the 100-day weighted moving average (WMA).
Its lowest level this week is also along the crucial support of $100, the highest swing in January and the upper side of the cup-and-handle pattern. As such, there are signs that it has formed a break-and-retest pattern, which often leads to a continuation.
The Average Directional Index (ADX) has dropped from 43 to the current 25 and is still pointing downwards. That is a sign that the stock’s downward trend is losing momentum.
There are signs that the stock has formed a falling wedge pattern, which normally leads to a bullish breakout. Therefore, there is a likelihood that it will soon bounce back in the coming days or weeks, potentially to the year-to-date high of $151.
RKLB stock chart | Source: TradingView
The other bullish catalyst for Rocket Lab is that its business is firing on all cylinders as demand continues rising. Electron, its small orbital launch vehicle continues seeing strong demand from governments and companies.
Its Hypersonic Accelerator Suborbital Test Electron (HASTE), its variant of Electron, is also seeing strong demand from the US Department of Defense as it accelerates hypersonic missile developments.
Most importantly, the company continues to take orders for Neutron, its medium-lift launch vehicle that will carry more payloads.
The most recent financial results showed that it booked 31 missions in the first quarter, with the management seeing an inflection point of across its orbital and suborbital launches. This is important as the company received a 20-launch order valued at $190 million from the DoD. It has also become a major name in the Golden Dome project.
READ MORE: RKLB stock suffers a brutal reversal as a bullish pattern begins to take shape
Analysts expect that Rocket Lab’s revenue growth has more room to run. Yahoo Finance data shows that the annual revenue will jump by 52% this year to $915 million. It will then grow by 41% next year to $1.29 billion. If this trend continues, it will hit the $5 billion milestone in the coming years.
Rocket Lab’s other catalyst is that it plans to launch Neutron later this year, with its deployment expected to increase gradually over time. A combination of Neutron, Electron, and Haste will lead to robust revenue growth over time.
By launching Neutron, the company will now start to focus on boosting its profitability.
Still, there are some risks to the thesis. The first one is that it is common for stocks to retreat after entering a major index like the Nasdaq 100. A good example of this is Robinhood, which has dropped sharply since its entry.
The other risk is that it may enter the distribution and markdown phases of the Wyckoff Theory. These phases are usually characterized by sharp declines in prices.
Further, Rocket Lab is not a cheap company as it trades at a forward price-to-sales ratio of 67, much higher than most companies. As such, there is a risk that it may go through a valuation reset.
Rocket Lab stock is among today’s weakest performers. What’s weighing on RKLB shares? What Does Rocket Lab’s Nasdaq-100 Inclusion Mean?Rocket Lab officially joined the Nasdaq-100 on Monday, a change that forces index-tracking funds and ETFs, including Invesco QQQ, which manages over $300 billion, to own the stock. The inclusion comes after a choppy stretch for space-sector proxies following Space Exploration Technologies Corp (SpaceX) IPO day on June 12, when RKLB sold off as capital rotated toward the new listing.
Rocket Lab Shatters Records with VICTUS HAZEMeanwhile, Rocket Lab late Monday launched the U.S. Space Force’s VICTUS HAZE mission 16 hours and 42 minutes after receiving the official Notice to Launch, reducing the previous record by more than 10 hours.
The company managed all operational phases of this mission, providing an end-to-end space service that encompassed spacecraft design, component fabrication, launch, and ongoing 24/7 on-orbit management.
The deployed Pioneer spacecraft is now fully commissioned and executing orbital maneuvers. The vehicle is currently conducting Rendezvous and Proximity Operations (RPO) to track another active spacecraft in low Earth orbit.
RKLB Stock: Key Technical Levels To WatchFrom a trend perspective, RKLB is still in a bullish long-term structure—up 194.39% over the past 12 months and trading 29.7% above its 200-day SMA at $74.34—but the near-term tape is correcting. The stock is now 17.8% below its 20-day SMA ($117.27) and 8.3% below its 50-day SMA ($105.15), which frames the current move as a pullback inside a broader uptrend rather than a confirmed trend break.
Momentum is the main watch item: MACD is below its signal line and the histogram is negative, which points to upside pressure fading versus the prior upswing. In plain terms, MACD compares faster and slower trend momentum, and being below the signal line often means rallies can stall until buyers regain control.
Key Resistance: $99.50 — a nearby pivot area where rebounds can stall, sitting just under the psychologically important $100 level. How Rocket Lab Compares to Industrials TodayRKLB is underperforming Industrials today by about 2.22 percentage points (down 3.97% vs. the sector down 1.75%), which suggests the move isn’t just "sector beta" and may reflect stock-specific positioning around the index rebalance. Industrials is also having a rough session overall, ranking 10 out of 11 sectors, only ahead of Materials, while Technology is the biggest drag at down 3.78%.
The move mirrors broader pressure in growth and "story" equities, with the Nasdaq 100 down about 0.6% in the same risk-off tape that saw Alphabet tumble more than 6%. That kind of megacap-led de-risking often spills into space and defense proxies, providing a benchmark for Rocket Lab because the stock trades like a high-beta growth name when liquidity tightens.
Zooming out, the sector trend has been constructive despite today’s dip, with Industrials up 2.49% over the past 30 days and up 8.20% over the past 90 days. That backdrop matters because it implies RKLB’s longer-term bid has been supported by a favorable tape for cyclicals, but today’s underperformance highlights that the stock’s near-term path is being driven more by flows and momentum than by broad sector strength.
What Is Rocket Lab Corporation and Its Business Model?Rocket Lab is a space company that builds rockets and spacecraft, offering end-to-end mission services for civil, defense and commercial customers. It designs and manufactures the Electron and Neutron launch vehicles and the Photon satellite platform, with operations spanning Launch Services and Space Systems.
That business mix is why Nasdaq-100 inclusion is a meaningful headline: index membership can increase passive ownership and daily liquidity for a company that sits at the intersection of aerospace manufacturing and "new space" growth.
Electron’s track record delivering satellites to orbit across national security, scientific research and Earth-observation use cases helps explain why investors often treat the stock as a liquid proxy for broader space-industry sentiment.
RKLB Stock Price Movement on TuesdayRKLB Stock Price Activity: Rocket Lab shares were down 4.00% at $96.28 at the time of publication on Tuesday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
The space industry is in the middle of a transformation. For years, investors focused on launch providers, treating rocket launches as the primary source of value. That model is changing.
Governments increasingly want companies that can build satellites, launch them, operate them, and respond quickly when national security demands it. The winners may not be the companies with the biggest rockets, but those that can provide complete mission solutions. That’s why Rocket Lab‘s (NASDAQ:RKLB | RKLB Price Prediction) latest Victus Haze mission may prove more important than the launch itself. For investors, it signals that Rocket Lab is evolving into something much larger than a small launch company.
Victus Haze Was About More Than a Rocket Launch According to Rocket Lab, the company launched the Victus Haze mission just 16 hours and 42 minutes after receiving a launch order from the U.S. Space Force. That set a new record for the military’s Tactically Responsive Space (TacRS) program.
On the surface, that sounds like a simple operational achievement. In reality, it demonstrated capabilities that few competitors can match.
What makes Victus Haze unique is that Rocket Lab served as the prime contractor. The company didn’t just launch the mission. It also built the satellite, integrated the payload, conducted mission planning, and now operates the spacecraft in orbit.
Here’s what Rocket Lab controlled during the mission:
Capability Rocket Lab Role Launch Vehicle Electron rocket Satellite Platform Pioneer spacecraft Mission Operations In-house Spacecraft Components In-house systems and subsystems Launch Execution In-house That level of vertical integration resembles traditional aerospace contractors more than a standalone launch provider.
The Defense Opportunity Is Now Much Larger The launch itself won’t materially change Rocket Lab’s financial results. The U.S. Space Force contract was worth approximately $32 million. In comparison Rocket Lab generated $601.8 million in revenue during 2025. A single $32 million contract is helpful, but it is not transformational. The opportunity comes from what Victus Haze proves.
The Pentagon increasingly wants responsive space capabilities that can deploy assets within days or even hours. As geopolitical tensions rise, governments need the ability to replace satellites, inspect spacecraft, and respond to threats quickly. Victus Haze demonstrated that Rocket Lab can provide all of those services under one roof.
That potentially positions the company for future contracts involving:
Space domain awareness Military satellite production Responsive launch services On-orbit inspection missions National security space operations Those markets are far larger than Rocket Lab’s traditional small-launch business.
Investors Should View Rocket Lab Differently Today For years, critics argued that launch alone would never be a large enough market to justify premium valuations across the space sector. Surprisingly, Rocket Lab appears to agree.
The company has spent the past several years building spacecraft systems, acquiring satellite component manufacturers, and expanding beyond launch services. Victus Haze provides tangible evidence that those investments are paying off.
Compare Rocket Lab to many smaller launch competitors and the distinction becomes clear. Most can sell a launch. Rocket Lab can increasingly sell an entire mission. That creates multiple revenue streams while reducing dependence on launch frequency alone.
Granted, execution risk remains. Rocket Lab still needs to prove that these defense opportunities translate into recurring contracts and growing cash flow. The company is also investing heavily in its larger Neutron rocket program, which carries development risk.
That said, Victus Haze reduced one important uncertainty: whether Rocket Lab’s broader aerospace strategy actually works. The answer appears to be yes.
Key Takeaway In short, Victus Haze is not important because it generated a $32 million contract. It matters because it demonstrated that Rocket Lab can function as a full-service aerospace and defense contractor. The mission showcased rapid launch, satellite manufacturing, mission operations, and spacecraft management in a single package.
For long-term investors, that changes the investment thesis. Rocket Lab is no longer just competing for launch contracts. It is positioning itself to compete for larger defense and space systems programs that could generate recurring revenue for years. Ultimately, Victus Haze may be remembered less as a launch and more as the moment Rocket Lab proved its business model extends far beyond the rocket itself.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) securities of a pending securities class action.
THE CASE: A class action seeks to recover damages for investors who purchased ERAS securities between January 14, 2025 and April 26, 2026.
YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify to recover your per-share losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
From a closing price of $21.49 on April 24, 2026, Erasca shares collapsed to $9.90 by the close of trading on April 28, 2026. That $11.59 per-share decline, representing a 53.9% loss of value, followed two corrective disclosures that stripped away what the lawsuit maintains was artificial inflation built on misleading preclinical comparisons and undisclosed safety and intellectual property risks. The last day to move for lead plaintiff is August 10, 2026.
The April 27, 2026 Pre-Market Disclosure
Before markets opened on April 27, 2026, Erasca filed a Form 8-K disclosing that Revolution Medicines had sent a letter alleging ERAS-0015 infringes U.S. Patent No. 12,409,225 and involves trade secret misappropriation. RevMed further alleged that Erasca had made "deceptive and untrue comparative statements" about ERAS-0015 versus RMC-6236. Shares fell from $21.49 to close at $19.15 that day, a decline of approximately $2.34 per share (10.9%).
The April 27, 2026 Post-Market Disclosure
After the close on the same day, Erasca filed a second Form 8-K reporting preliminary Phase 1 clinical data. That filing disclosed a patient death classified as a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5. The filing also conceded that all comparisons between ERAS-0015 and RMC-6236 were based on cross-study analyses, were "not based on any head-to-head clinical trials," and were "inherently limited." The next morning, shares opened at $10.51 and closed at $9.90, an additional decline of $9.25 per share (48.3%) from the prior close.
Alleged Investor Damages and Loss Causation
The lawsuit maintains that throughout the class period, the market price of ERAS common stock was artificially inflated by statements promoting ERAS-0015's alleged superiority over RevMed's RMC-6236. The complaint asserts the following sequence quantifies investor harm:
Erasca repeatedly claimed ERAS-0015 achieved "comparable antitumor activity to RMC-6236 at 1/10th of the dose" and demonstrated "8-21-fold higher binding affinity to cyclophilin A"These claims were presented at major investor conferences and in SEC filings without disclosing that comparisons were cross-study analyses rather than head-to-head trialsDefendants raised approximately $258.8 million in a January 2026 stock offering while these allegedly misleading comparisons were outstandingWhen the patent infringement letter and clinical safety data were disclosed on April 27-28, 2026, the artificial inflation was removed in two stages totaling $11.59 per shareThe combined decline of 53.9% reflected the market repricing ERAS shares to account for previously concealed patent, trade secret, and clinical safety risks
"When companies fail to disclose material information, shareholders may suffer significant losses. The two-stage correction in Erasca's stock price on April 27 and 28 quantifies the gap between what investors were told about ERAS-0015 and what was actually happening." -- Joseph E. Levi, Esq.
Join the ERAS recovery action or call Joseph E. Levi, Esq. at (888) SueWallSt.
ABOUT SUEWALLST -- Over the past 20 years, SueWallSt has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, SueWallSt has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the ERAS Lawsuit
Q: How much did ERAS stock drop? A: Shares fell approximately 53.9%, a decline of $11.59 per share, after Erasca disclosed a patent infringement letter from Revolution Medicines and a patient death in Phase 1 trials on April 27-28, 2026. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.
Q: What is the ERAS lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 10, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: What if I already sold my ERAS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: What do ERAS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What court was the ERAS class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Microsoft Corporation (NASDAQ: MSFT) securities of a pending securities class action.
THE CASE: A class action seeks to recover damages for investors who purchased Microsoft securities between May 1, 2025 and January 28, 2026.
YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify for recovery or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Microsoft shares traded above $550 during the Class Period as the Company promoted Copilot as a transformative enterprise AI product with "best-in-class" capabilities. The lead plaintiff deadline is August 11, 2026.
How an Enterprise AI Product Generates Revenue
An enterprise software company cannot sustain premium pricing for AI-powered productivity tools unless those tools deliver measurable workflow improvements, integrate seamlessly with existing systems, and retain users after initial deployment. Microsoft's Copilot family of products was positioned as exactly this kind of tool, embedded across Word, Excel, PowerPoint, Outlook, and Teams, and sold through paid "seats" to businesses worldwide. Management claimed Copilot was the "fastest-growing M365 portfolio product" ever, with paid commercial seats exceeding 430 million and adoption by over 90% of the Fortune 500.
The lawsuit contends that behind these adoption figures, Copilot suffered from fundamental operational failures that undermined its commercial viability.
Alleged Copilot Product Deficiencies by Category
The action claims Microsoft failed to disclose that Copilot experienced serious problems across multiple operational dimensions:
Brand positioning failures: Copilot's identity was fragmented across dozens of product versions with different features and capabilities, confusing both enterprise buyers and end usersUser experience deficiencies: The product allegedly failed to meet baseline expectations for generative AI writing, analysis, and content creation that management called "table stakes"Data siloing problems: Despite touting "Work IQ" as a differentiator that understood users' work context, Copilot allegedly could not effectively integrate data across Microsoft's own application ecosystemComputational capacity constraints: Microsoft was increasing total AI capacity by 80% and doubling its data center footprint, yet the filing asserts capacity remained insufficient to deliver consistent Copilot performanceInteroperability breakdowns: Copilot's integration with third-party ISV agents and enterprise workflows allegedly fell short of the seamless orchestration management described at investor conferences
The Operational Gap Between Claims and Alleged Reality
As detailed in the action, management portrayed Copilot as saving employees an average of 46 minutes daily at one major deployment and generating over 30 million employee interactions in six months at another. The complaint asserts these cherry-picked examples masked systemic product shortcomings that threatened the sustainability of seat growth and ARPU expansion that drove Microsoft's AI revenue narrative.
The filing states that organizational problems within Microsoft's AI division compounded these product-level issues, creating internal friction that slowed Copilot's development and deployment capabilities even as management publicly claimed innovation was "accelerating rapidly."
Start your claim now or call (888) SueWallSt.
"The complaint raises serious questions about whether investors received accurate information about the operational readiness of Microsoft's flagship AI product during a period when the Company was asking the market to value it as an AI leader," stated Joseph E. Levi, Esq.
Investors have until August 11, 2026 to seek lead plaintiff status.
SueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the MSFT Lawsuit
Q: Who is eligible to join the MSFT investor lawsuit? A: Investors who purchased MSFT stock or securities between May 1, 2025 and January 28, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.
Q: What specific misstatements does the MSFT lawsuit allege? A: The complaint alleges Microsoft made materially false or misleading statements regarding the success, adoption, and operational performance of its Copilot AI products while concealing significant brand positioning, data siloing, computational capacity, and interoperability problems. When the true state was revealed, the stock price declined.
Q: What do MSFT investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.
Q: What if I already sold my MSFT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, will release financial results for the second quarter of 2026 on Thursday, July 30, 2026, at approximately 7:00 AM EDT.
In addition, Tradeweb will host a conference call for investors.
WHO:
Billy Hult, CEO
Sara Furber, CFO
Ashley Serrao, Head of Treasury, FP&A and IR
WHAT:
A discussion of financial results for the second quarter of 2026 followed by a question-and-answer session
WHEN:
Thursday, July 30, 2026, at 9:30 AM EDT
A live webcast of the conference call, along with related presentation materials, will be available at https://investors.tradeweb.com/events-and-presentations.
To join the call via audio webcast, click here. To join the call via phone, click here to register in advance. Registered participants will receive an email confirmation with a unique PIN to access the conference call. An archived recording of the call will be available afterward at https://investors.tradeweb.com.
About Tradeweb Markets
Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 50 products to clients in the institutional, wholesale, retail and corporates markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 3,000 clients in more than 85 countries. On average, Tradeweb facilitated more than $2.8 trillion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.tradeweb.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading “Risk Factors” in the documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future events or performance and future events, our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if future events, our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of events, results or developments in future periods.
Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.
Freehold, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, today expressed strong support for the 21st Century ROAD to Housing Act, comprehensive bipartisan legislation designed to address the nation’s housing shortage by expanding supply, reducing costs, and modernizing regulations for manufactured housing.
Samuel A. Landy, President and Chief Executive Officer of UMH commented “Manufactured homes provide high-quality, affordable housing options for millions of American families, and this legislation removes outdated barriers that have limited their potential. By modernizing federal standards, the ROAD to Housing Act will lower production costs, improve financing access, and ease placement restrictions, enabling UMH to expand our communities, enhance resident offerings, and deliver even greater value to our shareholders and the families we serve. These reforms are poised to accelerate industry growth, complementing UMH’s ongoing initiatives in community development, home sales, and operational excellence. The Act includes key provisions that the Company believes will significantly benefit the manufactured housing sector and UMH’s portfolio of communities across the Northeast, Southeast, and Midwest. With 145 communities and 27,100 homesites, UMH is well-positioned to capitalize on increased demand for affordable, high-quality housing solutions.
“Improvements to the Title One financing program should allow more people to qualify for financing and achieve the American dream of home ownership, thereby increasing sales of homes that qualify for the program. Additionally, with the removal of the chassis requirement, we will be able to introduce a broader range of home designs and anticipate being able to increase the square footage of each home by utilizing multi-story homes. Building two residential units on one lot with one structure should reduce the cost of housing and increase the revenue per lot. The new law encourages zoning for innovative affordable housing which UMH provides.
“UMH remains committed to providing safe, well-maintained communities and supporting the American Dream of homeownership through manufactured housing.
“I would like to thank the Manufactured Housing Institute for their hard work advocating for our industry and their efforts to adopt this bill.”
Lesli Gooch, PH. D., Chief Executive Officer of the Manufactured Housing Institute commented “We commend Congress and the Administration for advancing this landmark housing package and recognizing the critical role manufactured housing has in addressing the nation’s housing supply challenges. This bill will expand the range of homes that can be built under the federal residential construction code, make it easier to site manufactured homes where they are most needed, and improve financing options for small dollar loans for manufactured homes. In short, the bill will be a shot in the arm to help high-quality manufactured homes make attainable homeownership possible for more families across the country.”
Key Benefits for Manufactured Housing and UMH Properties Include:
Removal of the Permanent Chassis Requirement: The legislation updates the federal definition of a “manufactured home” to allow units “with or without a permanent chassis.” This change is expected to reduce construction costs by thousands per home, enable innovative multi-story designs, larger floor plans, and more flexible installation options such as slab-on-grade or placement over basements. It also promotes uniformity in state laws for financing, titling, taxation, and zoning treatment, making manufactured homes more competitive in a broader range of locations, including urban infill sites.
Updates to FHA Title I Financing: Through the Property Improvement and Manufactured Housing Loan Modernization Act, the bill increases loan limits for FHA-insured manufactured housing and property improvement loans, expands eligible uses (including accessory dwelling units), and directs studies to further reduce barriers. These enhancements should improve affordability and accessibility for potential homebuyers, supporting higher occupancy and sales growth in our communities.
Easing of Zoning and Land-Use Barriers: Broader provisions in the Act promote housing supply through incentives for local governments, guidelines for zoning reforms, and support for factory-built housing. Combined with the chassis reform, this creates a more favorable environment for placing manufactured homes in diverse residential areas, aligning with UMH’s growth strategy in established and expanding markets.
UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,200 contain rental homes, and over 1,000 self-storage units. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina, Florida and Georgia. Included in the 145 communities are two communities in Florida, containing 363 sites, and one community in Pennsylvania, containing 113 sites, that UMH has an ownership interest in and operates through its joint ventures with Nuveen Real Estate.
Certain statements included in this press release which are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements are based on the Company’s current expectations and involve various risks and uncertainties. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, the Company can provide no assurance those expectations will be achieved. The risks and uncertainties that could cause actual results or events to differ materially from expectations are contained in the Company’s annual report on Form 10-K and described from time to time in the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Alert: Claims Focus on Alleged Misrepresentations About Weakening Veterinarian Adoption and Prescription Trends That Cost ZTS Investors $23.91 Per Share Following the Final Disclosure
, /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Zoetis Inc. (NYSE: ZTS) securities of a pending securities class action.
THE CASE: A class action seeks to recover damages for investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026.
YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
Zoetis shares fell $23.91 per share on May 7, 2026, the fourth decline in a series of successive disclosures, after the Company admitted that veterinarian prescription trends, clinic patient volume, and pet owner price sensitivity had all deteriorated materially. Investors have until July 27, 2026 to seek lead plaintiff status.
How Companion Animal Prescriptions Drive Zoetis Revenue
An animal health company dependent on veterinarian-prescribed therapies cannot sustain revenue growth when the professionals who write those prescriptions lose confidence in core products. Zoetis' four flagship Companion Animal brands, which collectively generated approximately 70% of total revenue, each required veterinarian authorization before reaching a pet owner. That structure meant veterinarian willingness to prescribe was the single most important operational lever for the Company's financial performance.
The filing states that throughout 2025 and into 2026, veterinarian adoption trends for Librela were sharply weakening following the FDA's December 2024 safety warnings about seizures and deaths in treated dogs. Simultaneously, prescription volumes for Simparica Trio and dermatology products Apoquel and Cytopoint were eroding as lower-priced competitors from Elanco captured market share.
Alleged Prescription Growth Deterioration by the Numbers
Simparica franchise posted 17% U.S. growth in Q1 2025 on $260 million in revenue, but the lawsuit contends this trajectory was unsustainable as Elanco's Credelio Quattro offered tapeworm coverage Trio lacked at a lower price point Librela had reached 86% clinic penetration by May 2025, yet the action claims veterinarians were increasingly cautious about prescribing it following reports of severe neurological events Dermatology products faced direct competition from Zenrelia, which Elanco marketed as comparable or superior to Apoquel in head-to-head studies at a lower cost By Q1 2026, the Company admitted that "share loss is being amplified by a derm market with declining patient volume in the clinic" Pet owners demonstrated "increased price sensitivity," further compressing prescription volumes across all franchises The parasiticides market itself was contracting, negatively impacting compliance rates and prescription refills Clinic Volume Decline and Price Sensitivity
As detailed in the action, the operational deterioration extended beyond competitive share loss. Patient volume inside veterinary clinics declined during the period, meaning fewer dogs were even being seen for the conditions Zoetis products treated. When combined with pet owners choosing lower-cost alternatives or delaying treatment altogether, the result was a compounding effect on Zoetis' prescription-dependent revenue model that management allegedly failed to disclose until May 2026.
Calculate your potential recovery or call (212) 363-7500.
"The complaint raises serious questions about whether investors received accurate information regarding the operational health of Zoetis' prescription-driven business model, particularly as veterinarian adoption trends and clinic volumes were allegedly deteriorating throughout the Class Period." -- Joseph E. Levi, Esq.
Start your claim now or contact Joseph E. Levi, Esq. at (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report. Motions for lead plaintiff must be filed with the Court by July 27, 2026.
Frequently Asked Questions About the ZTS Lawsuit
Q: Who is eligible to join the ZTS investor lawsuit? A: Investors who purchased ZTS stock or securities between January 14, 2025 and May 6, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.
Q: How much did ZTS stock drop? A: Shares fell approximately 21.5%, a decline of $23.91 per share, after the Company disclosed significant deterioration across its core Companion Animal business and sharply reduced full-year guidance on May 7, 2026. Investors who purchased shares during the Class Period at artificially inflated prices may be entitled to compensation.
Q: What specific misstatements does the ZTS lawsuit allege? A: The complaint alleges Zoetis made materially false or misleading statements regarding the durability of its Companion Animal growth, veterinarian adoption trends, competitive positioning, and market share across its flagship product franchises during the Class Period. When the true state was revealed, the stock price declined sharply.
Q: What do ZTS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What if I already sold my ZTS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the Class Period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Analyst’s Disclosure: I/we have a beneficial long position in the shares of CAR.UN:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.
Scorpio Tankers is poised for continued upside as strong tanker rates drive robust earnings and capital returns. STNG has locked in exceptional Q2 rates, supporting an estimated $4.75–$5.10 EPS and potential for further dividend hikes or aggressive buybacks. Despite a modest 2.2% yield, management prioritizes opportunistic buybacks, recently authorizing $500 million—nearly 12% of equity value.
FREMONT, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced the launch of the new IQ9N™ Microinverter for residential solar across the United States. Built with gallium nitride (GaN) technology, IQ9N Microinverters help enhance energy production from the latest high-power solar panels and are engineered to deliver peak performance over the system’s lifetime, with an industry-leading 97.5% CEC weighted efficiency and a 25-year limited warranty.
IQ9N Microinverters support 16 A of continuous DC current and 427 VA of continuous output power, pairing with today’s premium high-wattage residential solar panels to help maximize energy production from each module. They are backward compatible with IQ7™ and IQ8™ Series Microinverters and IQ® Batteries, enabling homeowners and installers to expand existing Enphase systems using similar installation methods and accessories.
GaN technology enables a peak efficiency of up to 97.8%, with cooler operation and optimized performance across conditions. Enphase’s GaN architecture reduces conduction losses and heat, improves long-term reliability based on engineering and lifecycle testing, maintains peak performance across seasons, and provides capacity to support emerging high-power solar panels. Read the technical white paper, "Enphase Adoption of GaN Bi-Directional Switch Technology for Distributed Power Electronics," for a more detailed view of Enphase's GaN architecture.
"Every hour our crew spends on a roof — and every time we have to go back — cuts into our margins," said Bill Ward, president at Elbac Solar. "The IQ9N Microinverters work with the installation process we already use, and because they're so dependable, we're not getting pulled back out for service calls. For installers, that's what a real win looks like."
"IQ9N Microinverters are a major leap forward in residential inverter performance," said Carlos Martínez Muñoz, president at Solar Roots, an installer of Enphase products in Puerto Rico. "The combination of GaN technology, higher efficiency, and support for the latest high-power panels lets us design better systems for our customers and unlock more energy from every roof."
IQ9N Microinverters are engineered to optimize energy from every panel across a wide range of conditions, including partial shading, complex roof layouts, and high-temperature environments. Like all Enphase microinverters, IQ9N Microinverters convert DC to AC at each panel, eliminating long high-voltage DC runs used in traditional string inverter designs and delivering a safer, all-AC architecture on the roof. Per-panel power conversion also keeps the rest of the system producing even if one panel is shaded, soiled, or offline.
"Enphase keeps setting the bar higher," said Mike Thompson, CEO of Golden Bear Solar. "IQ9N Microinverters pair perfectly with today's premium panels, and the distributed architecture means homeowners get more usable energy and a safer system on the roof."
"Homeowners want solar that just works, year after year, in any weather," said Kevin O'Donnell, CEO of O'Donnell Solar Co. "With IQ9N Microinverters, we can deliver that with confidence, and the cooler operating temperatures give us peace of mind on long-term reliability."
IQ9N Microinverters meet rigorous grid compliance standards and are NEMA Type 6 rated with a double-insulated, corrosion-resistant polymer housing and an operating temperature range of -40°C to +65°C, engineered to withstand extreme weather conditions. Built-in rapid shutdown capability helps reduce risk to utility workers and first responders. Homeowners can monitor system performance at the panel level, receive real-time alerts, and benefit from over-the-air software updates through the Enphase® App.
IQ9N Microinverters that are manufactured in U.S. facilities with domestic content are designed to be “FEOC compliant” (see Enphase website for details on “FEOC-compliant” products) and may help eligible projects qualify for domestic content bonus tax credits. The products also comply with Buy American Act standards for federal direct procurement contracts.
"Residential solar customers expect their systems to perform at the highest level for decades," said Aaron Gordon, senior vice president and general manager of the systems business unit at Enphase Energy. "IQ9N Microinverters combine our proven distributed architecture with GaN technology and support for the latest panels, giving homeowners the most powerful, efficient, and reliable Enphase microinverter we've ever built."
IQ9N Microinverters are backed by an industry-leading 25-year limited warranty. The product is available now in the United States through Enphase distribution partners.
Certain Enphase products may qualify as FEOC-compliant under IRS Notice 2025-08. Customers should consult their legal and tax advisors to confirm eligibility. Learn more about IQ9N Microinverters on the Enphase website.
About Enphase Energy, Inc.
Enphase Energy, a global energy technology company based in Fremont, CA, is the world's leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 87.8 million microinverters, with more than 5.2 million Enphase-based systems deployed in over 165 countries. For more information, visit https://enphase.com/.
This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy's technology and products, including safety, quality, and reliability; the suitability of IQ9N Microinverters for residential solar applications and the latest high-wattage residential solar panels; the expected benefits of gallium nitride–based technology, including higher efficiency, cooler operation, and improved long-term reliability; the expected benefits of Enphase's distributed microinverter architecture; the availability and timing of IQ9N Microinverter shipments; the qualification of certain products for domestic content, FEOC compliance, Buy America Act standards, and related incentive programs or federal procurement contracts; and the scope and terms of Enphase's limited warranty. These forward-looking statements are based on Enphase Energy's current expectations and assumptions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, market demand; competitive developments; changes in tax credits, incentive programs, and regulatory or compliance requirements; supply chain availability and costs; and other factors discussed in Enphase Energy's filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law.
Enphase Energy (ENPH - Free Report) closed at $47.22 in the latest trading session, marking a -9.9% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 1.44%. Meanwhile, the Dow experienced a drop of 0.09%, and the technology-dominated Nasdaq saw a decrease of 2.22%.
The stock of solar technology company has fallen by 18.15% in the past month, lagging the Oils-Energy sector's loss of 7.14% and the S&P 500's gain of 0.08%.
Market participants will be closely following the financial results of Enphase Energy in its upcoming release. On that day, Enphase Energy is projected to report earnings of $0.46 per share, which would represent a year-over-year decline of 33.33%. Simultaneously, our latest consensus estimate expects the revenue to be $291.74 million, showing a 19.66% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.12 per share and a revenue of $1.23 billion, signifying shifts of -28.38% and -16.78%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Enphase Energy. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Enphase Energy boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Enphase Energy is at present trading with a Forward P/E ratio of 24.68. This signifies no noticeable deviation in comparison to the average Forward P/E of 24.68 for its industry.
The Solar industry is part of the Oils-Energy sector. With its current Zacks Industry Rank of 160, this industry ranks in the bottom 35% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Key Takeaways ENPH introduces IQ9N microinverters built on GaN technology with 97.5% efficiency.ENPH ensures backward compatibility with IQ7, IQ8 systems and IQ Batteries for easy upgrades.ENPH expansion across the United States and Europe aims to boost shipments and drive near-term revenue growth. Enphase Energy, Inc. (ENPH - Free Report) announced the launch of its IQ9N Microinverter for residential solar across the United States. The product is domestically manufactured to satisfy U.S. domestic content requirements and comply with Foreign Entity of Concern regulations.
Key Benefits of Enphase’s IQ9N MicroinvertersBuilt on gallium nitride (GaN) technology, IQ9N Microinverters are designed to boost energy production from the latest high-power solar panels while delivering strong performance throughout the system’s lifespan. They offer an industry-leading 97.5% California Energy Commission weighted efficiency and come with a 25-year limited warranty.
The IQ9N Microinverters support 16 Amperes of continuous Direct Current (“DC”) and 427 Volt-Amperes of continuous output power, allowing them to pair with premium high-wattage residential solar panels and maximize energy generation from each module. They are also backward compatible with IQ7 and IQ8 Series Microinverters as well as IQ Batteries, enabling homeowners and installers to expand existing Enphase systems using similar installation methods and accessories.
IQ9N Microinverters are designed to maximize energy production from each solar panel under a variety of conditions, including partial shading, complex roof configurations and high-temperature environments. Like all Enphase microinverters, they convert DC to Alternating Current (“AC”) at the panel level, eliminating the need for long high-voltage DC runs common in traditional string inverter systems and providing a safer, all-AC rooftop architecture.
Growth ProspectsAccording to a Mordor Intelligence report, the solar energy market size in terms of the installed base is expected to witness a CAGR of 19.91% during 2026-2031. This strong market outlook presents significant growth opportunities for leading solar companies such as Enphase.
In June 2026, ENPH also announced the launch of its new IQ9N Microinverter for residential solar applications across key European markets. The company also plans to expand the availability of the IQ9N Microinverter to additional countries worldwide in the coming months.
This expansion of Enphase’s product portfolio is expected to support higher product shipments and contribute to revenue growth in the quarters ahead.
Stocks to WatchOther prominent solar players that are anticipated to benefit from the expanding global solar energy market are as follows:
Nextpower Inc. (NXT - Free Report) : In June 2026, the company announced the global launch of its redesigned NX Gemini two-in-portrait (2P) solar tracker system. This launch marks a broader expansion of Nextpower’s solar solutions portfolio across Europe.
NXT boasts a long-term (three to five years) earnings growth rate of 11.44%. The Zacks Consensus Estimate for fiscal 2027 sales is pegged at $4.26 billion, which implies an improvement of 19.6%.
Tigo Energy, Inc. (TYGO - Free Report) : In April 2026, the company announced the launch of Inverter Power Output Control for its 3.8-kilowatt Tigo EI Inverter in the United States. The inverter is designed to support both standalone solar systems and solar-plus-storage setups, allowing homeowners to integrate battery backup as part of future upgrades.
The Zacks Consensus Estimate for TYGO’s 2026 sales is pegged at $132.2 million, which indicates a rise of 27.7%. The Zacks Consensus Estimate for its 2026 earnings per share (EPS) stands at 4 cents, which calls for an improvement of 116.7%.
SolarEdge Technologies, Inc. (SEDG - Free Report) : In March 2026, the company announced the commercial launch of its next-generation three-phase SolarEdge Nexis residential solar and storage system in Germany. SolarEdge Nexis features a completely new design architecture, spanning from the inverter to the battery, enabling homeowners to add storage capacity incrementally and align it with their evolving energy needs.
The Zacks Consensus Estimate for SEDG’s 2026 sales is pegged at $1.40 billion, which suggests a jump of 18.4%. The Zacks Consensus Estimate for its 2026 EPS stands at 3 cents, which implies a surge of 101.3%.
ENPH Stock Price MovementOver the past six months, shares of Enphase Energy have risen 43.7% compared with the industry’s growth of 1.9%.
Image Source: Zacks Investment Research
ENPH’s Zacks RankThe company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation (NYSE:TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, announced today that it has executed a lease for 92,000 square feet in Kearny, New Jersey with a third-party logistics provider. The lease will commence June 30, 2026 and will expire December 2031.
Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey; Los Angeles; Miami; San Francisco Bay Area; Seattle; and Washington, D.C.
Additional information about Terreno Realty Corporation is available on the company’s web site at www.terreno.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. We caution investors that forward-looking statements are based on management’s beliefs and on assumptions made by, and information currently available to, management. When used, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “result,” “should,” “will,” “seek,” “target,” “see,” “likely,” “position,” “opportunity,” “outlook,” “potential,” “enthusiastic,” “future” and similar expressions which do not relate solely to historical matters are intended to identify forward-looking statements. These statements are subject to risks, uncertainties, and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control, including risks related to our ability to meet our estimated forecasts related to stabilized cap rates and those risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other public filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, or projected. We expressly disclaim any responsibility to update our forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on results and trends at the time they are made, to anticipate future results or trends.
AU, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, both members of the Taiho group, today announced that the first patient has been dosed in a Phase 1 clinical trial of ARC-02, a CD79b-targeted antibody-drug conjugate (ADC) for the treatment of non-Hodgkin lymphoma (NHL).
ARC-02 selectively binds CD79b-positive B-cells and delivers monomethyl auristatin E (MMAE), a clinically validated anti-cancer payload, directly to tumor cells. It is the first clinical candidate generated using Araris’ proprietary AraLinQ® ADC technology and Arastatin™ linker-payload, designed for precise intracellular release and minimization of impact on healthy tissue.
“Dosing the first patient with ARC-02 marks a pivotal milestone for Araris as we enter the clinic and begin translating our innovative ADC platform into potential benefits for patients,” said Philipp Spycher, PhD, CSO and scientific founder of Araris.
“While ARC-02 is initially being developed for hematological malignancies, the differentiated safety profile observed in preclinical studies may also support its broader application across additional disease indications, including autoimmune diseases,” said Isabella Attinger-Toller, PhD, CTO and co-founder of Araris.
“This milestone represents the first human experience with the novel Araris platform and marks Taiho’s expansion into the clinical development of ADCs for oncology,” said Harold Keer, MD, PhD, Chief Medical Officer at Taiho Oncology. “We look forward to results from this trial and advancing other agents from Araris into the clinic.”
About AraLinQ®
AraLinQ® is Araris’ ADC technology, which enables site-specific payload attachment to a privileged attachment site on a specific amino acid residue (Q295) within the native antibody Fc framework. Preclinical data demonstrate that when a payload is attached to this site using Araris’ proprietary linkers, the antibody maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong isopeptide bond resulting in exceptional stability. Once entering a cancer cell via antibody-mediated internalization, the linker can be easily broken to release the payload. All three of these properties are key factors to enable efficient payload delivery and maximize ADC efficacy. AraLinQ® linkers are hydrophilic, rendering them soluble and avoiding their clumping in water-based solutions like blood. In addition, this linker can have unique branching structures that make it possible to create ADCs that carry multiple payloads of different types. AraLinQ® allows for the generation of ADCs in one step using “off-the-shelf,” antibodies that are native or engineered. The process is fast, cost-efficient and can be easily upscaled without the need for custom antibody synthesis.
About ArastatinTM
Arastatin™ is a novel linker-payload technology based on MMAE and an Araris proprietary hydrophilic peptide linker. Arastatin™ is designed specifically to be used with Araris’ site-specific ADC technology AraLinQ® which enables the direct conjugation of the MMAE linker-payload to Q295 of native, off-the-shelf antibodies in one step. In preclinical studies, Arastatin™ based ADCs were found to be highly potent, stable and well-tolerated among different antibodies compared to commercially available ADCs.
About Araris Biotech AG
Araris Biotech AG, a wholly owned subsidiary of Taiho Pharmaceutical Co., Ltd., is a leading biotech company pioneering the future of antibody-drug conjugates and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of anti-cancer agents that aim to deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. For more information about our science and pipeline, please visit https://www.ararisbiotech.com/.
About Taiho Oncology, Inc.
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.
For more information, visit https://www.taihooncology.com/, and follow us on LinkedIn and X.
Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd. Araris and AraLinQ are trademarks of Araris Biotech AG.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether ADC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On June 3, 2026, ADC “announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).” Although ADC’s treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared to the nine deaths recorded for the immunotherapy arm.
On this news, ADC’s stock price fell $2.05 per share, or 66.56%, over the following two trading sessions, to close at $1.03 per share on June 5, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility
Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026
, /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise.
As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent. The reduction is driven by the expected completion of the LOTIS-5 and LOTIS-7 trials this year, as well as operational efficiencies. With these changes, the Company is resourced to deliver on its key clinical, regulatory and manufacturing activities while maintaining the full externally facing medical affairs and commercial footprint to support ZYNLONTA.
"As we further assess the Phase 3 LOTIS-5 trial outcomes, including feedback from key medical experts, we continue to believe in the favorable overall benefit-risk profile and look forward to our pre-supplemental Biologics License Application (sBLA) meeting with the U.S. Food and Drug Administration in August," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This strategic reorganization will enable us to increase our financial flexibility as we prepare for upcoming LOTIS-5 regulatory milestones and continue building on the broader opportunity for ZYNLONTA through LOTIS-7 and support for the indolent lymphoma investigator-initiated trials (IITs). We are grateful to all of our employees for their efforts to help make a meaningful impact for patients and thank them for their important contributions to our company."
The Company is preparing for a scheduled pre-sBLA meeting with the FDA in August 2026 to discuss the potential regulatory path forward for ZYNLONTA in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) following the recent topline data results from the Phase 3 LOTIS-5 trial. ADC Therapeutics expects to submit an sBLA in the fourth quarter of 2026.
In addition, the Company continues to advance the ZYNLONTA franchise through the ongoing Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with glofitamab in 2L+ DLBCL, with data anticipated by the end of 2026, as well as through support for Phase 2 IITs exploring ZYNLONTA across indolent lymphomas.
ADC Therapeutics expects the reorganization to generate annualized estimated cost savings of approximately $10 million. ADC Therapeutics estimates that it will incur one-time pre-tax charges of approximately $3 million for employee severance, benefits and related termination costs, the majority of which will be recognized in the second quarter of 2026. The Company has an expected cash runway at least into 2028.
About ZYNLONTA®
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com.
ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).
ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the cost and effects of the strategic restructuring and workforce reduction including our ability to achieve the estimated cost savings; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and acceptance of an sBLA submission related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions; our ability to identify and execute value-maximizing options and the cost and impact of such options; our expected cash runway into at least 2028 assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company's ability to sustain or grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing, results and publication of the Company's clinical trials including LOTIS-7; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040
, /PRNewswire/ -- NNN REIT, Inc. (NYSE: NNN) ("NNN" or the "Company"), a real estate investment trust ("REIT"), today announced the exercise of its $200 million incremental term loan option under its senior unsecured term loan facility, increasing the aggregate facility size to $500 million (the "Term Loan"). The incremental borrowings carry identical terms to the existing $300 million term loan (after giving effect to the amendments described below). The Term Loan matures on February 15, 2029, with two one-year extension options. NNN expects to use proceeds from the incremental term loan for general corporate purposes.
In anticipation of the incremental term loan, NNN entered into a $100 million forward starting swap that fixes SOFR at 3.43% through February 15, 2029.
"We are pleased with today's transactions, which enhance our financial flexibility, provide capital to fund our business plans, and lower our cost of capital," said Vincent H. Chao, Chief Financial Officer. "We greatly appreciate the continued support and long-standing relationships with our bank group."
Additionally, the Company amended the pricing grids on the Term Loan and its existing senior unsecured revolving credit facility, (the "Revolving Credit Facility"). Based on NNN's current credit ratings, the applicable SOFR-based margin was lowered to 0.800% from 0.850% for all outstanding Term Loan borrowings and 0.725% from 0.775% for all Revolving Credit Facility borrowings.
Wells Fargo Securities, LLC and BofA Securities, Inc., served as the Joint Lead Arrangers and Joint Bookrunners, with Wells Fargo Bank, National Association acting as the Administrative Agent and Bank of America, N.A. acting as the Syndication Agent.
Truist Securities, Inc., PNC Capital Markets LLC, U.S. Bank National Association, Royal Bank of Canada and TD Bank, N.A., served as Joint Lead Arrangers, with Truist Bank, PNC Bank, National Association, U.S. Bank National Association, Royal Bank of Canada, TD Bank, N.A., and Mizuho Bank Ltd., acting as Documentation Agents. Sumitomo Mitsui Banking Corporation, New York Branch, and Raymond James Bank also participated in the transaction.
About NNN REIT, Inc.
NNN is a REIT that invests in high-quality properties subject generally to long-term, net leases with minimal ongoing capital expenditures. As of March 31, 2026, the Company owned 3,711 properties across all 50 states, the District of Columbia and Puerto Rico, encompassing approximately 39.6 million square feet of gross leasable area, with a weighted average remaining lease term of 10.1 years. For additional information, please visit www.nnnreit.com.
Crocs (CROX - Free Report) closed at $121.14 in the latest trading session, marking a -2.15% move from the prior day. This change lagged the S&P 500's daily loss of 1.44%. Meanwhile, the Dow experienced a drop of 0.09%, and the technology-dominated Nasdaq saw a decrease of 2.22%.
The footwear company's stock has climbed by 12.1% in the past month, exceeding the Consumer Discretionary sector's loss of 1.97% and the S&P 500's gain of 0.08%.
The investment community will be closely monitoring the performance of Crocs in its forthcoming earnings report. On that day, Crocs is projected to report earnings of $4.3 per share, which would represent year-over-year growth of 1.65%. In the meantime, our current consensus estimate forecasts the revenue to be $1.15 billion, indicating a 0.1% decline compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $13.67 per share and revenue of $4.08 billion. These totals would mark changes of +9.27% and +0.97%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Crocs. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.02% lower within the past month. Crocs currently has a Zacks Rank of #3 (Hold).
Investors should also note Crocs's current valuation metrics, including its Forward P/E ratio of 9.06. This signifies a discount in comparison to the average Forward P/E of 15.4 for its industry.
Investors should also note that CROX has a PEG ratio of 1.28 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Textile - Apparel stocks are, on average, holding a PEG ratio of 2.01 based on yesterday's closing prices.
The Textile - Apparel industry is part of the Consumer Discretionary sector. This group has a Zacks Industry Rank of 156, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
On June 24, 2026, we present a DCF analysis for Northrop Grumman Corp NOC , a company currently facing a challenging price performance context with a year-to-date decline of 9.3% and a one-month drop of 7.2%. Below are key highlights from our analysis:
DCF Earnings-based intrinsic value of $435.16 compared to the current price of $513.22 (margin of safety: -17.9%) DCF Free Cash Flow (FCF)-based intrinsic value of $290.99, indicating a second opinion on valuation GF Score™ of 86/100, suggesting a high reliability of the DCF inputs What Is NOC Worth? DCF Earnings-Based Model The DCF earnings-based model for Northrop Grumman Corp utilizes a two-stage approach to estimate intrinsic value. In the first stage, we project earnings growth over the next ten years at a rate of 8.2%, followed by a terminal growth phase at a reduced rate of 4% for the subsequent ten years. The discount rate applied is 11%, derived from the risk-free rate and equity risk premium.
Parameter Value Current EPS (TTM, excl. non-recurring) $30.60 10-Year Growth Rate 8.2% 10-Year Treasury Rate 4.49% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the two-stage DCF model is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 8.2%, discounted at 11% $266.60 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $168.56 Intrinsic Value Growth + Terminal $435.16 With the current price at $513.22, the intrinsic value of $435.16 indicates that Northrop Grumman is fairly valued, with a margin of safety of -17.9%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research suggests that stock prices correlate more closely with earnings than with free cash flow. For further details, visit the NOC DCF Calculator.
What Does the Free Cash Flow DCF Say? The Free Cash Flow (FCF)-based intrinsic value for Northrop Grumman stands at $290.99. When comparing this to the earnings-based intrinsic value of $435.16, the two models diverge significantly. The FCF model suggests that the stock is modestly overvalued, with a margin of safety of -76.4%.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for Northrop Grumman is calculated at $557.59, providing a third perspective on valuation. GF Value™ is GuruFocus' proprietary measure, which considers historical trading multiples, past business growth, and future performance estimates. While the DCF earnings model suggests fair valuation, the FCF model indicates overvaluation, whereas GF Value™ suggests the stock is undervalued. This divergence highlights the importance of considering multiple valuation methods. For more information, visit the GF Value™ page.
What Does NOC's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtested data from 2006 to 2021.
Metric Rating GF Score™ 86/100 Financial Strength 6/10 Profitability 8/10 Growth 7/10 Valuation 10/10 Momentum 7/10 With a predictability rank of 0/5 stars, it is important to note that higher predictability ratings typically indicate that the DCF model is more reliable for the stock. For further insights, visit the NOC stock page.
Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to growth rate and discount rate assumptions. Stocks with low predictability ratings, such as Northrop Grumman, tend to produce less reliable DCF estimates. Additionally, the terminal growth rate of 4% is a simplifying assumption that may not reflect future market conditions accurately.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find that Northrop Grumman Corp presents a mixed picture. While the DCF earnings model suggests fair valuation, the FCF model indicates modest overvaluation, and the GF Value™ suggests it is undervalued. Overall, the consensus leans towards the stock being fairly valued.
For the full DCF analysis, visit the NOC DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is NOC's intrinsic value based on DCF?
According to our analysis, the earnings-based intrinsic value is $435.16, while the FCF-based intrinsic value is $290.99.
Is NOC overvalued or undervalued?
The DCF earnings model suggests fair valuation, while the FCF model indicates modest overvaluation. The GF Value™ suggests it is undervalued, creating a mixed consensus.
How reliable is the DCF model for NOC?
Given the predictability rank of 0/5, the DCF model for NOC may be less reliable compared to stocks with higher predictability ratings.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
ZEELAND, Mich. and STEINHAGEN, Germany, June 24, 2026 (GLOBE NEWSWIRE) -- Gentex Corporation and Hörmann today announced a strategic agreement to integrate Hörmann’s connected garage door opener technology into HomeLink, the automotive industry’s leading car-to-home automation system.
The partnership will enable Gentex customers across Europe to control compatible Hörmann garage door systems via HomeLink, securely triggering garage door open/close commands from the HomeLink app or directly from a connected vehicle through the HomeLink cloud.
HomeLink is the automotive industry’s most trusted and comprehensive car-to-home automation system. The latest version utilizes radio frequency, Long-Range Bluetooth®, and cloud-based technologies to activate garage doors, gates, lights, and other smart home devices directly from the vehicle. HomeLink is available on nearly 300 vehicle models from over 50 automaker brands, with approximately 110 million units currently in operation worldwide.
Hörmann, Europe’s leading provider of gates, doors, door frames, operators, access control systems, and storage solutions, offers a wide range of connected operator solutions that allow users to conveniently monitor and control their access points via smartphone apps. Through this integration, Hörmann customers will gain seamless in-vehicle control and expanded remote access capabilities via the HomeLink ecosystem.
“This partnership represents an important step in expanding connected vehicle-to-home experiences across Europe,” said Thorsten Lünstroth, Head of Product Management at Hörmann. “By integrating with HomeLink, we are enabling our customers to enjoy more convenient, secure, and intelligent access to their homes directly from their vehicles.”
“It’s exciting to expand HomeLink’s cloud-based garage door control capabilities through our partnership with Hörmann,” said Neil Boehm, chief technology officer and chief operating officer at Gentex. “Hörmann is a highly respected brand in the European access solutions market, and this collaboration strengthens HomeLink’s position as the most versatile and comprehensive car-to-home automation system — capable of supporting leading smart home technologies around the world.”
The integration will support remote monitoring, secure activation, and enhanced user convenience, while maintaining the reliability and performance expected from both companies’ technologies. This collaboration further advances Gentex’s strategy to expand HomeLink’s global ecosystem through partnerships with leading smart home and access control providers.
About Hörmann
The Hörmann Group is Europe’s leading manufacturer of gates and doors. At over 40 highly specialized plants in Europe, North America, and Asia, more than 6,000 employees develop and manufacture high-quality gates, doors, frames, operators, access control systems, and storage solutions for use in residential and commercial properties.
The global Hörmann Group is headquartered in the East Westphalian town of Steinhagen near Bielefeld. The family-run company most recently reported annual revenue of more than 1 billion euros. For more information, visit www.hoermann.com.
About Gentex
Founded in 1974, Gentex Corporation (NASDAQ: GNTX) is a technology company that leverages its core competencies, strategic partnerships, acquisitions, and ongoing research to create market-leading positions in a variety of verticals. You can view some of the Company’s latest technology at www.gentex.com.
Gentex Media Contact
Craig Piersma
(616) 772-1590 x4316 [email protected]
Investors with an interest in Computers - IT Services stocks have likely encountered both TD SYNNEX (SNX) and Dynatrace (DT). But which of these two companies is the best option for those looking for undervalued stocks?
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Coursera, Inc. (NYSE: COUR), a leading global online learning platform, has posted materials for today’s supplemental post-merger modeling call to its investor relations website at investor.coursera.com.
Conference Call Details
As previously announced, Coursera will hold a conference call where the company’s chief financial officer, Mike Foley, will provide an overview of the combined company’s full year 2026 financial profile following the close of its merger with Udemy, Inc. on May 11, 2026. Prepared remarks will be followed by an analyst question-and-answer session today, June 23, 2026, at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time).
A live, audio-only webcast of the conference call and supplemental materials can be found on our investor relations page at investor.coursera.com. For those unable to listen to the broadcast live, an archived replay will be accessible in the same location for one year.
Disclosure Information
In compliance with disclosure obligations under Regulation FD, Coursera announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission (“SEC”), press releases, company blog posts, public conference calls, and webcasts, as well as via Coursera’s investor relations website.
About Coursera
Coursera was launched in 2012 by Andrew Ng and Daphne Koller with a mission to provide universal access to world-class learning. Coursera partners with leading university and industry partners to offer a broad catalog of content and credentials, including courses, Specializations, Professional Certificates, and degrees. Coursera’s platform innovations — including AI-powered personalized guide and features, like Role Play and Course Builder, and role-based solutions like Skills Tracks — enable instructors, partners, and companies to deliver scalable, personalized, and verified learning. Institutions worldwide rely on Coursera to upskill and reskill their employees, students, and citizens in high-demand fields such as GenAI, data science, technology, and business, while learners globally turn to Coursera to master the skills they need to advance their careers. Coursera is a Delaware public benefit corporation and a B Corp. Coursera recently combined with Udemy to create one of the world’s most comprehensive skills development platforms.
Coursera, Inc. (NYSE: COUR), a leading global online learning platform, has posted materials for today’s supplemental post-merger modeling call to its investor relations website at investor.coursera.com.
Conference Call Details
As previously announced, Coursera will hold a conference call where the company’s chief financial officer, Mike Foley, will provide an overview of the combined company’s full year 2026 financial profile following the close of its merger with Udemy, Inc. on May 11, 2026. Prepared remarks will be followed by an analyst question-and-answer session today, June 23, 2026, at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time).
A live, audio-only webcast of the conference call and supplemental materials can be found on our investor relations page at investor.coursera.com. For those unable to listen to the broadcast live, an archived replay will be accessible in the same location for one year.
Disclosure Information
In compliance with disclosure obligations under Regulation FD, Coursera announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission (“SEC”), press releases, company blog posts, public conference calls, and webcasts, as well as via Coursera’s investor relations website.
About Coursera
Coursera was launched in 2012 by Andrew Ng and Daphne Koller with a mission to provide universal access to world-class learning. Coursera partners with leading university and industry partners to offer a broad catalog of content and credentials, including courses, Specializations, Professional Certificates, and degrees. Coursera’s platform innovations — including AI-powered personalized guide and features, like Role Play and Course Builder, and role-based solutions like Skills Tracks — enable instructors, partners, and companies to deliver scalable, personalized, and verified learning. Institutions worldwide rely on Coursera to upskill and reskill their employees, students, and citizens in high-demand fields such as GenAI, data science, technology, and business, while learners globally turn to Coursera to master the skills they need to advance their careers. Coursera is a Delaware public benefit corporation and a B Corp. Coursera recently combined with Udemy to create one of the world’s most comprehensive skills development platforms.
Source Code: COUR-IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20260623736875/en/
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 24:
Navigator Holdings Ltd. (NVGS - Free Report) : This global operator of a fleet of liquefied gas carriers carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 29.5% over the last 60 days.
Navigator has a price-to-earnings ratio (P/E) of 10.84, compared with 22.97 for the S&P 500. The company possesses a Value Score of B.
Byline Bancorp, Inc. (BY - Free Report) : This bank holding company for Byline Bank carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.2% over the last 60 days.
Byline has a price-to-earnings ratio (P/E) of 10.82, compared with 22.97 for the S&P 500. The company possesses a Value Score of B.
Neurocrine Biosciences, Inc. (NBIX - Free Report) : This developer of innovative therapies for neurological and endocrine disorders carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.4% over the last 60 days.
Neurocrine has a price-to-earnings ratio (P/E) of 17.67, compared with 22.97 for the S&P 500. The company possesses a Value Score of B.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Learn more about the Value score and how it is calculated here.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Byline Bancorp, Inc. (BY - Free Report) : This bank holding company for Byline Bank has seen the Zacks Consensus Estimate for its current year earnings increasing 6.2% over the last 60 days.
Navigator Holdings Ltd. (NVGS - Free Report) : This global operator of a fleet of liquefied gas carriers has seen the Zacks Consensus Estimate for its current year earnings increasing 29.5% over the last 60 days.
Neurocrine Biosciences, Inc. (NBIX - Free Report) : This developer of innovative therapies for neurological and endocrine disorders has seen the Zacks Consensus Estimate for its current year earnings increasing 14.4% over the last 60 days.
TFI International Inc. (TFII - Free Report) : This transportation and logistics company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.6% over the last 60 days.
Bunge Global SA (BG - Free Report) : This agricultural and food company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.3% over the last 60 days.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Paccar (PCAR - Free Report) ended the recent trading session at $116.78, demonstrating a -2.78% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.44%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 2.22%.
The truck maker's stock has climbed by 9.85% in the past month, exceeding the Auto-Tires-Trucks sector's loss of 3.79% and the S&P 500's gain of 0.08%.
Analysts and investors alike will be keeping a close eye on the performance of Paccar in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.32, signifying a 3.65% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $7.1 billion, reflecting a 1.92% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.59 per share and a revenue of $27.7 billion, indicating changes of +11.58% and +5.59%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Paccar. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Paccar is holding a Zacks Rank of #3 (Hold) right now.
Looking at valuation, Paccar is presently trading at a Forward P/E ratio of 21.5. This signifies a premium in comparison to the average Forward P/E of 20.13 for its industry.
Meanwhile, PCAR's PEG ratio is currently 1.12. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Automotive - Domestic industry had an average PEG ratio of 0.99.
The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
, /PRNewswire/ - Wheaton Precious Metals™ Corp. ("Wheaton" or the "Company") is pleased to announce that it has again been named to Corporate Knights' 2026 Best 50 Corporate Citizens in Canada (the "Best 50"), ranking 13th overall.
"We are proud to once again be recognized by Corporate Knights as one of Canada's best corporate citizens," said Haytham Hodaly, President and Chief Executive Officer of Wheaton. "This consistent recognition reflects our commitment to disciplined capital allocation and partnering with mine operators who prioritize responsible business practices."
The Best 50 is one of Canada's most established sustainability benchmarks, assessing more than 350 large companies using a transparent, data-driven methodology focused on the share and growth of revenues tied to sustainable activities. Wheaton's inclusion reflects the quality of its portfolio, its strong organic growth profile, and its approach to partnering with leading operators, underpinned by a broader commitment to conducting business responsibly and sustainably.
Earlier this year, Wheaton was also recognized among Corporate Knights' 2026 global 100 most sustainable corporations in the world.
To learn more about Wheaton's sustainability approach and commitments, please visit: www.wheatonpm.com/Sustainability.
About Wheaton Precious Metals Corp.
Wheaton Precious Metals is the world's premier precious metals streaming company, providing shareholders with access to a high-quality portfolio of low-cost, long-life mines around the world. Through strategic streaming agreements, Wheaton partners with mining companies to secure a portion of their future precious metals production. Committed to responsible mining practices, Wheaton employs due diligence practices with a goal of unlocking long-term value for shareholders while supporting the broader mining industry to deliver the commodities society needs through access to capital. Wheaton's shares are listed on the Toronto Stock Exchange, New York Stock Exchange and London Stock Exchange under the symbol WPM.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation concerning the business, operations and financial performance of Wheaton. Forward-looking statements, which are all statements other than statements of historical fact, include, but are not limited to, statements with respect to innovative mining technology, the potential success of that technology, and its ability to be commercialized, ESG and climate change strategy, targets and commitments and climate scenario analysis by Wheaton and at mineral stream interests currently owned by Wheaton (the "Mining Operations"). Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Wheaton to be materially different from those expressed or implied by such forward-looking statements including (without limitation) risks related to the ability to identify innovative mining technology, the potential success of that technology and the ability to commercialize that technology, risks related to the ability to achieve ESG and climate change strategy, targets and commitments at both Wheaton and the Mining Operations and other risks discussed in the section entitled "Description of the Business – Risk Factors" in Wheaton's Annual Information Form for the year ended December 31, 2025 and the risks identified under "Risks and Uncertainties" in Wheaton's Management's Discussion and Analysis ("MD&A") for the year ended December 31, 2025, both available on SEDAR+ and in Wheaton's Form 6-K filed March 12, 2026, all available on EDGAR (the "Disclosure"). Forward-looking statements are based on assumptions management currently believes to be reasonable, including (without limitation) that Wheaton will be able to identify innovative mining technology, ESG and climate change strategy, targets and commitments at both Wheaton and the Mining Operations will be achieved, there will be no material adverse change in the market price of commodities, that estimations of future production from the Mining Operations and mineral reserves and resources are accurate, that the mining operations from which Wheaton purchases precious metals will continue to operate, that each party will satisfy their obligations in accordance with the precious metals purchase agreements, and such other assumptions and factors as set out in the Disclosure
Key Takeaways IBKR added ChatGPT and Grok, extending AI-assisted trading to options and futures.IBKR clients can link accounts to ChatGPT, Grok or Claude without passwords or API keys.IBKR requires review and approval of every AI instruction before orders reach markets. Interactive Brokers (IBKR - Free Report) is further accelerating its push into artificial intelligence (AI) by adding ChatGPT and Grok to its expanding suite of AI-enabled investing solutions. The enhancement will expand AI-assisted trading beyond stocks and exchange-traded funds (ETFs) to include options, futures and futures options, enabling investors to interact with a broader range of markets through conversational prompts.
The launch builds on IBKR's earlier integration with Anthropic's Claude and highlights the broker's efforts to simplify market analysis and trading workflows without compromising investor oversight.
Now, existing customers can connect their IBKR accounts to ChatGPT, Grok or Claude within minutes at no additional cost, using their standard IBKR credentials and without sharing passwords or API keys with third-party providers.
As interest in AI-powered investing gains momentum, IBKR is positioning itself at the forefront of this shift. Users can leverage AI assistants to assess portfolio exposures, explore hedging strategies, track technical indicators such as the relative strength index, benchmark performance against major ETFs and create futures order instructions.
However, execution remains firmly in investors’ hands, as every AI-generated instruction must be reviewed and approved through a dedicated AI Instructions tab before reaching the market.
How IBKR Builds on AI & Platform InvestmentsThe latest AI integrations complement an expanding suite of tools already available across Interactive Brokers' platforms. AI Screeners allow investors to search more than 70,000 global stocks using conversational prompts, while Investment Themes help users explore opportunities tied to trends, such as clean energy and cloud computing.
IBKR also introduced Connections, which maps relationships among companies, ETFs, derivatives and thematic datasets from a single interface. Ask IBKR enables clients to query portfolio exposure and concentration in plain language, and AI News Summaries provide concise updates tailored to holdings and watch lists.
Beyond AI, Interactive Brokers recently launched a unified interface for prediction-market contracts offered through Kalshi, CME and ForecastEx. The company has also added stablecoin funding capabilities, expanded access to Coinbase Derivatives products and benefited from growing engagement, with overnight trading volumes climbing to 8.1 million trades in the first quarter of 2026 from 2.8 million a year earlier.
For IBKR, these investments are part of a long-term strategy to simplify investing while broadening access to institutional-grade capabilities. By steadily adding new asset classes, intelligent research tools and innovative trading workflows, the company aims to help investors make better-informed decisions while ensuring that final control over every transaction remains in the hands of clients.
IBKR’s Price Performance & Zacks RankIn the last six months, Interactive Brokers shares have gained 46.7%, outperforming the industry’s 4.1% growth.
Image Source: Zacks Investment Research
Currently, the company carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
IBKR’s Competitive LandscapeInteractive Brokers is not alone in embedding AI into investing workflows. Several brokerages and investment platforms have accelerated their AI initiatives over the past year, though their approaches differ.
Among retail brokers, Robinhood Markets, Inc. (HOOD - Free Report) launched AI-enabled trading accounts that allow users to connect AI agents, including Claude and ChatGPT-based tools, to analyze portfolios and execute stock trades within predefined limits. Robinhood is also extending AI capabilities to credit-card purchases through agent-driven workflows.
Charles Schwab (SCHW - Free Report) incorporated an AI assistant into its platform, with a focus on helping investors navigate research, educational content and trading tools. Rather than emphasizing autonomous trading, Schwab's approach centers on improving investor support and platform usability.
Interactive Brokers Group, Inc. (IBKR - Free Report) closed at $94.70 in the latest trading session, marking a -2.19% move from the prior day. This change lagged the S&P 500's 1.44% loss on the day. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 2.22%.
The company's shares have seen an increase of 19.02% over the last month, surpassing the Finance sector's gain of 3.16% and the S&P 500's gain of 0.08%.
The upcoming earnings release of Interactive Brokers Group, Inc. will be of great interest to investors. The company is expected to report EPS of $0.59, up 15.69% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $1.66 billion, indicating a 12.16% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.46 per share and a revenue of $6.9 billion, signifying shifts of +12.33% and +12.14%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Interactive Brokers Group, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Interactive Brokers Group, Inc. holds a Zacks Rank of #3 (Hold).
In terms of valuation, Interactive Brokers Group, Inc. is currently trading at a Forward P/E ratio of 39.41. Its industry sports an average Forward P/E of 14.63, so one might conclude that Interactive Brokers Group, Inc. is trading at a premium comparatively.
We can additionally observe that IBKR currently boasts a PEG ratio of 2.68. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Financial - Investment Bank industry was having an average PEG ratio of 1.09.
The Financial - Investment Bank industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 104, placing it within the top 43% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
, /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WIMI" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, has completed systematic benchmark testing on fully parameterized quantum convolutional neural networks. Its research team has proposed a quantum neural network model inspired by classical convolutional neural networks. Throughout the entire computational process, this model only adopts two-qubit interactions. It not only retains the simplicity of the network architecture but also greatly lowers the implementation difficulty of quantum circuits, laying a crucial foundation for its practical deployment on noisy intermediate-scale quantum computers in the future.
Unlike traditional deep learning networks, classical convolutional neural networks generally rely on massive parameters and sophisticated hierarchical structures to perform feature extraction. For instance, in image classification tasks, convolutional layers continuously scan input images to extract local features, after which pooling layers compress feature dimensions, and fully connected layers ultimately generate classification decisions. Although this architecture has achieved remarkable success, the training and inference costs surge exponentially as model scales keep expanding.
The research team at WIMI holds that quantum computing is inherently capable of processing high-dimensional feature spaces. A quantum system consisting of n qubits can represent a 2ⁿ-dimensional state space simultaneously, which enables it to tackle complex pattern recognition tasks with far fewer parameters than classical algorithms. This potential advantage has driven the research team to rethink the implementation of convolutional neural networks and attempt to build convolutional quantum neural network architectures via quantum gate operations.
To this end, WIMI has designed a fully parameterized Quantum Convolutional Neural Network (QCNN) architecture. The network mainly comprises a quantum data encoding layer, a quantum convolutional layer, a quantum pooling layer, a feature compression layer and a quantum classification layer. Distinct from many complex quantum networks built on multi-qubit gate operations, this model takes two-qubit interactions as its basic computational unit, which effectively controls circuit depth and mitigates noise accumulation.
In the data input phase, raw classical images first go through preprocessing modules for dimensionality reduction and normalization. Given the limited number of qubits supported by current quantum hardware, researchers need to map high-dimensional image data onto a finite qubit space. To address this challenge, WIMI has investigated multiple classical data preprocessing strategies including principal component analysis, feature selection and image compression techniques, ensuring the input data adapts to quantum computing resource constraints while preserving core information.
Once preprocessing finishes, data proceeds to the quantum encoding stage. As a cornerstone of quantum machine learning, quantum encoding converts classical data into quantum state representations. WIMI has systematically compared a range of quantum encoding schemes such as angle encoding, amplitude encoding and hybrid encoding methods. Experimental results reveal that different encoding strategies directly determine the network's representation capacity and training efficiency. Angle encoding leverages rotation gates to map data into the parameter space of quantum states, featuring straightforward implementation and strong noise robustness. By contrast, amplitude encoding can express higher-dimensional data with fewer qubits yet comes with relatively higher implementation complexity.
After data is encoded into quantum states, the network executes quantum convolution operations. Classical convolutional neural networks extract features by sliding convolutional kernels over local regions, while QCNN implements convolution via parameterized two-qubit gates. WIMI has constructed a series of trainable quantum gate arrays that establish correlations between different features through quantum entanglement. Since quantum states can exist as superpositions of multiple states concurrently, the network can process numerous potential feature combinations in parallel within a single computation, delivering more efficient feature extraction than classical convolution methods.
Notably, the model follows a fully parameterized design principle. While certain quantum gate parameters are often fixed in conventional quantum neural networks, the architecture proposed by WIMI allows all key quantum gate parameters to be updated during training. This design substantially boosts the model's expressive power, enabling it to learn intricate data distribution patterns.
Following quantum convolution, the network enters the quantum pooling stage. Classical pooling layers reduce feature dimensions through max pooling or average pooling, whereas quantum pooling screens valid information via measurement, entanglement reconstruction and quantum state compression. By gradually cutting down the number of qubits involved in computation, the network reduces subsequent computational complexity while retaining critical feature information.
From an information processing perspective, this mechanism mirrors the feature abstraction process in classical deep learning. As network layers deepen, low-level features including edges, textures and shapes in input images are progressively converted into high-level semantic abstract representations, supporting the final classification task.
WIMI has tested multiple QCNN configurations covering diverse parameterized quantum circuit architectures, data encoding schemes, loss functions and optimization algorithm combinations. Experimental results demonstrate that QCNN achieves outstanding classification performance across most test scenarios. Most importantly, even with far fewer parameters than classical convolutional neural networks, QCNN matches or even exceeds the classification accuracy of traditional CNNs. This outcome proves that quantum neural networks deliver higher parameter utilization efficiency; in other words, quantum models can learn richer data features with fewer trainable parameters and thus achieve superior overall performance.
Further analysis by WIMI attributes this competitive edge to the high-dimensional feature representation capability enabled by quantum entanglement. In classical neural networks, information exchange between neurons is constrained by connection topology, yet quantum entanglement builds non-classical correlations among multiple qubits, empowering the network with stronger representation capacity under limited computing resources. To enhance training stability, the research team has thoroughly explored optimization workflows. Training quantum neural networks frequently suffers from vanishing gradients and flat parameter regions, an issue known as the barren plateau phenomenon. To resolve this problem, the team evaluated various optimizers including stochastic gradient descent, Adam optimizer and quantum-specific optimization algorithms, and analyzed how different cost functions affect model training.
Experimental results verify that well-designed parameter initialization strategies and optimization pipelines can effectively ease training difficulties, allowing the network to converge stably within fewer training epochs. This research delivers valuable practical experience for training large-scale quantum neural networks in the future.
It is foreseeable that with the continuous advancement of quantum computing technologies, quantum convolutional neural networks will evolve into a core component of next-generation intelligent computing. From current classical data classification experiments to large-scale artificial intelligence applications in complex future scenarios, QCNN exhibits enormous potential to reshape the evolution of machine learning. WIMI's research not only advances the theoretical development of quantum machine learning but also pioneers innovative technical routes for developing efficient, low-parameter and high-performance new artificial intelligence systems, laying a solid foundation for the advent of the quantum intelligence era.
About WiMi Hologram Cloud
WiMi Hologram Cloud Inc. (NASDAQ: WiMi) focuses on holographic cloud services, primarily concentrating on professional fields such as in-vehicle AR holographic HUD, 3D holographic pulse LiDAR, head-mounted light field holographic devices, holographic semiconductors, holographic cloud software, holographic car navigation, metaverse holographic AR/VR devices, and metaverse holographic cloud software. It covers multiple aspects of holographic AR technologies, including in-vehicle holographic AR technology, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR virtual advertising technology, holographic AR virtual entertainment technology, holographic ARSDK payment, interactive holographic virtual communication, metaverse holographic AR technology, and metaverse virtual cloud services. WiMi is a comprehensive holographic cloud technology solution provider. For more information, please visit http://ir.wimiar.com.
Translation Disclaimer
The original version of this announcement is the officially authorized and only legally binding version. If there are any inconsistencies or differences in meaning between the Chinese translation and the original version, the original version shall prevail. WiMi Hologram Cloud Inc. and related institutions and individuals make no guarantees regarding the translated version and assume no responsibility for any direct or indirect losses caused by translation inaccuracies.
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.
Zions (ZION - Free Report) is headquartered in Salt Lake City, and is in the Finance sector. The stock has seen a price change of 14.66% since the start of the year. The financial holding company is paying out a dividend of $0.45 per share at the moment, with a dividend yield of 2.68% compared to the Banks - West industry's yield of 2.57% and the S&P 500's yield of 1.44%.
Looking at dividend growth, the company's current annualized dividend of $1.80 is up 2.3% from last year. Over the last 5 years, Zions has increased its dividend 3 times on a year-over-year basis for an average annual increase of 5.20%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Zions's current payout ratio is 28%, meaning it paid out 28% of its trailing 12-month EPS as dividend.
Looking at this fiscal year, ZION expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $6.44 per share, with earnings expected to increase 5.23% from the year ago period.
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. It's important to keep in mind that not all companies provide a quarterly payout.
High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, ZION is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of #3 (Hold).
New research shows 80% of parents wish they had taken more family vacations with their children
ORLANDO, Fla.--(BUSINESS WIRE)--Club Wyndham®, the nation’s largest vacation club built around comfort, connection and together time, today launched 17 Summers, a new campaign inspired by a simple but powerful truth: the moments we share today become the memories we cherish for a lifetime.
Built around the concept that parents have 17 summers with their children before adulthood begins, the campaign encourages families to slow down, reconnect and make the most of the seasons that shape family stories. As a cornerstone vacation club brand of Travel + Leisure Co., Club Wyndham created 17 Summers to celebrate the moments that stay with us long after summer ends.
The campaign is supported by new data from a survey conducted by Talker Research for Club Wyndham, which found that:
91% of parents say time seems to move faster as their children get older, with 66% saying a single year can feel like two. 79% say they have limited time left to travel with their family before their children grow out of family vacations. 80% wish they had taken more vacations with their kids when they were younger. 90% say family travel is one of the best ways to build lasting memories. The findings underscore a growing desire among Americans to be more intentional about how they spend their time together as schedules become increasingly busy and childhood seems to pass more quickly.
"Vacation memories have a way of becoming part of your life story," said Annie Roberts, senior vice president of Club and Owner Services at Travel + Leisure Co. "As a mom, I've experienced firsthand how quickly childhood moves from one season to the next. The inspiration behind 17 Summers is simple: to remind people that the moments they'll cherish the most years from now are often the ones they're living right now. Years later, it’s rarely the itinerary you remember—it's the laughter, the traditions and the time spent with the people who matter most. Vacation creates space for those moments, and we want to help people make the most of them."
As part of the campaign, Club Wyndham will invite families to share their own 17 Summers stories through user-generated content, social media activations and digital experiences celebrating the traditions, adventures and small moments that make summer memorable.
The campaign will also feature storytelling content that reflects the evolving nature of family vacations—from young children discovering their first beach vacation to teenagers planning adventures with friends and creating new traditions together.
Make This Summer Count
To help families make the most of the time they have together, Club Wyndham is pairing the campaign with a special vacation offer designed to inspire one more getaway before summer fades into memory.
Now through Sept. 22, travelers can save 17% on rental stays at participating Club Wyndham properties by using promo code 17SUMMERS at checkout. Whether making family memories at Club Wyndham Kingsgate in Williamsburg, enjoying a getaway at Club Wyndham La Belle Maison in New Orleans, or spending time by the Pacific at Club Wyndham Oceanside Pier Resort in California, travelers can find destinations designed to bring loved ones together and create the "watch this" moments that one day become "remember when" memories.
Families can follow along and share their own 17 Summers memories with Club Wyndham on Instagram (@ClubWyndham) and Facebook (@ClubWyndham) using #17Summers.
To book a stay and take advantage of the 17 Summers vacation offer, visit ClubWyndhamVacationRentals.com/offers/17summers.
More information about Club Wyndham and its benefits can be found at ClubWyndham.com.
SURVEY METHODOLOGY: Data from a survey conducted by Talker Research on behalf of Club Wyndham from June 3 to June 12, 2026, with a sample of 2,000 parents of school-aged children who celebrate occasions and have gone on vacation within the past year.
OFFER DETAILS: Book and travel by September 22, 2026. Enter promo code 17SUMMERS at checkout for 17% off your entire stay. Two-night minimum length of stay required. Valid for new reservations only. Reservations are subject to availability. Reservations may be limited during certain holidays. Cannot be combined with any other offer. All monetary amounts are noted in U.S. Dollars unless otherwise noted. Offer rewards are available only on resort bookings made online via ClubWyndhamVacationRentals.com and rewards are distributed via email after resort arrival.
About Club Wyndham®
Club Wyndham® is the nation’s largest vacation club built around comfort, connection and together time. With access to more than 100 resorts in sought-after destinations, Club Wyndham serves as a vacation home base for travelers who treasure making memories with the people they love. Spacious resort suites offer the comforts of home, including fully equipped kitchens, separate living and dining areas, and private bedrooms, creating space to settle in, spread out and enjoy meaningful time together. Whether continuing favorite family traditions or starting new ones, Club Wyndham helps families and friends create stories that span generations and gives them countless reasons to keep coming back. All Club Wyndham resorts participate in Wyndham Rewards®, the award-winning travel loyalty program with access to more than 60,000 hotels, vacation club resorts and vacation rentals worldwide. Club Wyndham is a cornerstone vacation club brand of Travel + Leisure Co. (NYSE), the world’s largest vacation ownership business.
For more information, visit ClubWyndham.com. Connect with us on Facebook and Instagram.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have to say about Waste Management (WM - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Waste Management currently has an average brokerage recommendation (ABR) of 1.66, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.66 approximates between Strong Buy and Buy.
Of the 29 recommendations that derive the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 65.5% and 3.5% of all recommendations.
Brokerage Recommendation Trends for WM
Check price target & stock forecast for Waste Management here>>>
While the ABR calls for buying Waste Management, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is WM a Good Investment?In terms of earnings estimate revisions for Waste Management, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $8.15.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Waste Management. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Waste Management.
On June 22, 2026, XP Inc XP shares rose 4.5% today, with the current price at $15.99. The stock has traded within a 52-week range of $14.80 to $23.13.
GF Value™ verdict: 51.9% undervalued with a fair value of $33.21. GF Score™ of 72/100 indicates an above-average potential for long-term returns. Most notable signal: No insider transactions in the last 3 months. Is XP Overvalued or Undervalued? XP Inc XP currently trades at $15.99, while the GF Value™ estimates its fair value at $33.21. This suggests that XP is 51.9% undervalued, indicating a substantial margin of safety for potential investors. However, the GF Valuation label indicates that this stock may also be a possible value trap, prompting investors to think twice before making decisions. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the undervaluation presents an opportunity, it is important to consider the risks involved, particularly given the stock's recent performance and the warning sign from the GF Valuation label. This stock’s potential upside must be weighed against its historical volatility and current market sentiment.
How Does XP's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 8.7x 13.7x (5-Year Median) Forward P/E 7.8x N/A The current P/E (TTM) of 8.7x is significantly below its 5-year median P/E of 13.7x, indicating that the stock is trading below its historical valuation. This P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that XP is undervalued in the context of its historical performance.
What Does XP's GF Score™ Tell Us? Metric Rating GF Score™ 72/100 Financial Strength 3/10 Profitability 6/10 Growth 9/10 Valuation 2/10 Momentum 7/10 The GF Score™ of 72/100 suggests that XP has above-average potential for long-term returns. Its strongest area is growth, with a score of 9/10, indicating robust future prospects. Conversely, the valuation score of 2/10 highlights significant concerns regarding its current pricing compared to intrinsic value, emphasizing caution in the investment approach.
What Are Insiders Doing with XP Stock? In the past three months, there have been no insider transactions in XP Inc XP stock. This lack of activity may suggest that insiders are either confident in the current valuation or are waiting for a more favorable market condition before making any moves. The absence of insider buying could also indicate a lack of urgency to capitalize on the company's current pricing.
What This Means for Investors Based on the GF Value™ assessment, XP Inc XP appears to be undervalued at its current price of $15.99, with a fair value estimation of $33.21. However, potential investors should remain cautious due to the identified risks and the possible value trap indicated by the GF Valuation label.
For the complete analysis, visit the XP Inc XP stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is XP's GF Score™?
XP's GF Score™ is 72/100, indicating above-average potential for long-term returns based on key financial metrics.
Is XP overvalued or undervalued?
XP is currently undervalued, trading at $15.99 compared to a fair value of $33.21, representing a potential upside of 51.9%.
What is XP's P/E ratio?
XP's current P/E ratio is 8.7x, which is 37% below its 5-year median of 13.7x, indicating it is trading below its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
